[PDF] Withdrawal of, and alternatives to, valproate-containing medicines in girls and women of childbearing potential who have a psychiatric illness

British Association for Psychopharmacology - BAP
British Association for Psychopharmacology
Publication date:
14 December 2018


New regulatory requirements relating to valproate-containing medicines necessarily have a significant impact on the overall care and management of many pregnant women, and girls and women of childbearing potential, who suffer from bipolar disorder or other psychiatric disorders. The Psychopharmacology Committee of the Royal College of Psychiatrists (with additional input from the Faculty of Perinatal Psychiatry and the British Association for Psychopharmacology) have therefore collaboratively developed the following guidance relating to prescribing decisions regarding valproate preparations in women of childbearing potential. We describe recent regulatory statements regarding valproate prescriptions, summarise evidence for alternatives to valproate, provide advice on how women who are currently undergoing treatment with valproate-containing preparations can be switched to alternative treatments, and provide a link to the recommended annual risk acknowledgment form to facilitate discussions with patients about hazards associated with valproate-containing medicines.